The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Structured treatment interruption in patients with alveolar echinococcosis
Open accessAbstract
In human alveolar echinococcosis (AE), benzimidazoles are given throughout life because they are only parasitostatic. It has been a longstanding goal to limit treatment, and recent reports suggest that, in selected cases, benzimidazoles may be parasitocidal. Previously, we showed that positron -emission tomography (PET) using [18 F]fluoro-deoxyglucose discriminates active from inactive lesions in AE. We have now performed a 3-year prospective study in 23 patients and conducted a structured treatment interruption in those without signs of PET activity. Disease progression was further assessed by ultrasound, computerized tomography, laboratory parameters, and clinical examination.We found PET-negative lesions in 15 of 23 patients and benzimidazoles were discontinued in these patients. After 18 months, patients were reevaluated, and, of the 15 initially PET-negative patients, 8 showed either new activity on PET (n = 6) or signs of clinical progression (n = 2). Reinitiation of benzimidazoles halted parasite growth again. No further progression was detected after 36 months. PET had a sensitivity of 91% for the detection of active lesions. In conclusion, despite successful suppression of metabolic activity, in most cases benzimidazoles do not kill the parasite. PET is a reliable tool for assessing metabolic activity and for timely detection of relapses. Neither duration of treatment, kind of treatment, lesion size, calcifications, or regressive changes reliably indicate parasite death. We discourage the discontinuation of benzimidazoles in inoperable AE even after many years of treatment. However, patients with a poor compliance of benzimidazole intake or patients suffering from side effects to benzimidazoles might be assessed for PET negativity. If permanent discontinuation of benzimidazoles is attempted, the course of disease should be followed by PET. (Hepatology 2004;39:509-517.)
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Long-term mebendazole therapy may be parasitocidal in alveolar echinococcosis
Ammann, R. W., Fleiner-Hoffmann, A., Grimm, F., & Eckert, J. (1998) · Journal of Hepatology · doi:10.1016/s0168-8278(98)80129-3 · Cited by 69
Cited by
Expert consensus for the diagnosis and treatment of cystic and alveolar echinococcosis in humans
Brunetti, E., Kern, P., & Vuitton, D. A. (2010) · Acta Tropica · doi:10.1016/j.actatropica.2009.11.001 · Cited by 2,183
Self-citation(2017) · Advances in Parasitology · doi:10.1016/bs.apar.2016.09.006 · Cited by 502
Basu, S., Chryssikos, T., Moghadam-Kia, S., Zhuang, H., Torigian, D. A., & Alavi, A. (2009) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2008.08.004 · Cited by 254
Treatment of echinococcosis: albendazole and mebendazole – what else?
Hemphill, A., Stadelmann, B., Rufener, R., Spiliotis, M., Boubaker, G., Müller, J., Müller, N., Gorgas, D., & Gottstein, B. (2014) · Parasite · doi:10.1051/parasite/2014073 · Cited by 173
Metadata
- Authors
- Reuter, S., Buck, A., Manfras, B., Kratzer, W., Seitz, H. M., Darge, K., Reske, S. N., & Kern, P.
- Venue
- Hepatology
- Published
- 2004-02
- Volume
- 39
- Issue
- 2
- Pages
- 509-517
- ISSN
- 0270-9139 (ISSN-L)
- OpenAlex
- W2037622579
- Cited by
- 171
- References
- 1
- FWCI
- 4.44
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Structured treatment interruption in patients with alveolar echinococcosis. https://app.cochat.ai/papers/10.1002/hep.20078
- The paper
- Reuter, S., Buck, A., Manfras, B., Kratzer, W., Seitz, H. M., Darge, K., Reske, S. N., & Kern, P. (2004). Structured treatment interruption in patients with alveolar echinococcosis. Hepatology. https://doi.org/10.1002/hep.20078
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.